Should You Hold Bio-Techne Corp. (TECH) For the Long Term?
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets started the year with a rally due to optimism about a strong economy and expectations of moderating inflation and lower interest rates. However, concerns over slowing earnings from major Technology companies, geopolitical tensions, and an upcoming announcement on tariffs led to a sharp decline in equities by the end of the first quarter. Investors sought safety, driving U.S. Treasury yields down. The Conestoga Small Cap Composite returned -11.35% (net) in the first quarter compared to the Russell 2000 Growth Index's -11.12% return. The Conestoga SMid Cap Composite returned -5.73% compared to the Russell 2500 Growth Index's -10.80% return. The Conestoga Micro-Cap Composite returned -8.24% vs the Russell Microcap Growth Index's return of -17.75%. Finally, the Conestoga Mid Cap Composite returned 0.96% (net), compared to the Russell Midcap Growth Index's -7.12% return. Please check the top 5 holdings of the fund for a better understanding of their best picks for 2025.
In its first-quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.846 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -9.53%, and its shares lost 34.35% of their value over the last 52 weeks. On May 1, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $49.63 per share.
Conestoga Capital Advisors stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter:
"Bio-Techne Corporation (NASDAQ:TECH) makes and distributes biological research supplies used by researchers around the globe. The company reported a strong quarter, with 9% organic revenue growth and a recovery in large pharmaceutical customer orders. That said, shares came under pressure due to increased uncertainty around the U.S. regulatory and funding environment. We believe the noise around the funding environment is a near-term headwind but the long-term demand for new drug development will remain robust."
A biopharmaceutical researcher proficiently using laboratory instruments.
Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we covered Bio-Techne Corporation (NASDAQ:TECH) and shared Aristotle Atlantic Large Cap Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1
Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.5% while next quarter's revenue guidance was 0.6% above. While some research tools & consumables stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 2% since the latest earnings results. With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Bio-Techne reported revenues of $316.2 million, up 4.2% year on year. This print was in line with analysts' expectations, but overall, it was a mixed quarter for the company with a solid beat of analysts' EPS estimates. "Despite a dynamic macroenvironment, the Bio-Techne team once again executed at a high level and delivered strong third quarter results," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. Interestingly, the stock is up 3.3% since reporting and currently trades at $49.21. Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it's free. Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Danaher reported revenues of $5.74 billion, flat year on year, outperforming analysts' expectations by 2.7%. The business had a very strong quarter with an impressive beat of analysts' organic revenue and EPS estimates. However, the results were likely priced into the stock as it's traded sideways since reporting. Shares currently sit at $185. Is now the time to buy Danaher? Access our full analysis of the earnings results here, it's free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.58 billion, down 5.9% year on year, falling short of analysts' expectations by 1.6%. It was a softer quarter as it posted a miss of analysts' organic revenue estimates and a slight miss of analysts' EPS estimates. Avantor delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 16.2% since the results and currently trades at $12.96. Read our full analysis of Avantor's results here. With roots dating back to the precision balance innovations of Swiss engineer Erhard Mettler, Mettler-Toledo (NYSE:MTD) manufactures precision weighing instruments, analytical equipment, and product inspection systems used in laboratories, industrial settings, and food retail. Mettler-Toledo reported revenues of $883.7 million, down 4.6% year on year. This print beat analysts' expectations by 1%. Zooming out, it was a slower quarter as it produced a miss of analysts' full-year EPS guidance estimates. The stock is up 8.2% since reporting and currently trades at $1,141. Read our full, actionable report on Mettler-Toledo here, it's free. Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE:A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets. Agilent reported revenues of $1.67 billion, up 6% year on year. This number topped analysts' expectations by 2.7%. More broadly, it was a mixed quarter as it failed to impress in some other areas of the business. Agilent had the weakest full-year guidance update among its peers. The stock is flat since reporting and currently trades at $111.98. Read our full, actionable report on Agilent here, it's free. In response to the Fed's rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed's 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump's presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Prosecutors seek record $250 million from fugitive drug lord
Dutch prosecutors said Monday they were seeking to confiscate a record $253 million from one of Europe's most notorious drug lords, thought to be hiding in Sierra Leone. The illegal assets amassed by Jos Leijdekkers, also known as "Bolle Jos" or "Chubby Jos," were proceeds from cocaine trafficking, as well as purchases of gold and luxury items, the public prosecutors said. Leijdekkers is thought to have made 114 million euros from 14 cocaine shipments over less than a year. According to intercepted communications, the 33-year-old also spent 47 million euros on 975 kilograms of gold over less than six months. The kingpin additionally bought real estate including a hotel in Turkey and apartments in Dubai, the prosecutors alleged. Luxury goods including two Bentley cars, designer bags, jewellery and watches, were also added to the total of illicit assets, bringing the total to $253 million. "This is... only a first step towards tracing Leijdekkers' assets," the prosecutors said. A Rotterdam court last June sentenced Leijdekkers in absentia to 24 years in prison for ordering a murder and organizing cocaine shipments. He is on Europol's most-wanted list, with the European police body offering over $225,000 for information leading to his arrest. "Leijdekkers is considered to be one of the key players in international cocaine trafficking," according to Europol. In January, Dutch authorities said they were "absolutely certain" he was hiding out in Sierra Leone. The BBC reported that Dutch prosecutor Wim de Bruin said the fugitive's return to the Netherlands was of "the highest priority." Images apparently showing Leijdekkers in the company of officials as high as President Julius Maada Bio have sparked speculation the cocaine lord has cozied up to Sierra Leone's political class -- including the president's daughter. Suspicions he was in Sierra Leone arose after the country's First Lady Fatima Bio posted pictures and a video on social media that showed a man strongly resembling Leijdekkers at a religious service, also attended by President Bio. Exiled Sierra Leone opposition figure Mohamed Mansaray has accused Bio and his government of "offering refuge" to the drug lord. According to Mansaray, Leijdekkers has coupled up with the president's daughter Agnes Bio, who is seen accompanying the drug lord in the images. Leijdekkers is also believed to be involved in the disappearance and death of Naima Jillal, a woman who went missing in 2019 after she got into a car in Amsterdam, according to Europol. Intercepted messages allegedly showed that Leijdekkers "played an important role in Jillal's disappearance," the agency said. "For a long time, there was no trace of Naima Jillal, until photos of a woman believed to be her were found on a phone seized in the Marengo investigation," Europol said. "The photos show that she was most likely tortured and is probably no longer alive." January 6 defendant refuses Trump's pardon The wonderfully weird world of artist Luigi Serafini Everything we know about the Boulder attack on Israeli hostage march
CNBC
3 hours ago
- CNBC
The front end of the Treasury curve is attractive, says JPMorgan's Priya Misra
Priya Misra, JPMorgan Asset Management fixed income portfolio manager, joins 'Squawk Box' to discuss the state of the economy, impact of tariff uncertainty, U.S. Treasury market, yield curve trends, and more.
